Abstract
Objective In patients with type 2 diabetes mellitus (T2DM), it is unknown whether acylcarnitine changes in the patient's plasma as diabetic peripheral neuropathy (DPN) occurs. The purpose of the present study was to investigate the correlation between acylcarnitines and DPN in Chinese patients with T2DM. Methods A total of 508 patients admitted to the First Affiliated Hospital of Jinzhou Medical University were included in this study, and all of whom were hospitalized for T2DM from January 2018 to December 2020. The diagnostic criteria for DPN were based on the 2017 Chinese Guidelines for the Prevention of Type 2 Diabetes. The contents of 25 acylcarnitine metabolites in fasting blood were determined by mass spectrometry. The measured acylcarnitines were classified by factor analysis, and the factors were extracted. To determine the correlation between acylcarnitines and DPN, binary logistic regression analysis was applied. Results Among the 508 T2DM patients, 270 had DPN. Six factors were extracted from 25 acylcarnitines, and the cumulative contribution rate of variance was 61.02%. After the adjustment for other potential confounding factors, such as other carnitines and conventional risk factors, Factor 2 was positively associated with an increased risk of DPN (OR: 1.38, 95% CI: 1.13-1.69). Factor 2 contained acetylcarnitine (C2), propionylcarnitine (C3), butylcarnitine (C4), and isovalerylcarnitine (C5). Conclusions Plasma levels of short-chain acylcarnitines (C2, C3, C4, and C5) were positively associated with DPN risk.
Highlights
According to statistics, the global incidence of diabetes among adults was 8.4% in 2017 and will rise to 9.9% by 2045
A total of 508 patients with type 2 diabetes mellitus (T2DM) admitted to the First Affiliated Hospital of Jinzhou Medical University from January 2018 to December 2020 were included for a cross-sectional study to explore the relationship between blood acylcarnitines and diabetic peripheral neuropathy (DPN) in T2DM patients
The present study showed that the C2, C3, C4, and C5 shortchain acylcarnitines in Factor 2 were positively correlated with the risk of DPN in T2DM and that this positive correlation existed after adjusting for other confounding factors
Summary
In patients with type 2 diabetes mellitus (T2DM), it is unknown whether acylcarnitine changes in the patient’s plasma as diabetic peripheral neuropathy (DPN) occurs. The purpose of the present study was to investigate the correlation between acylcarnitines and DPN in Chinese patients with T2DM. A total of 508 patients admitted to the First Affiliated Hospital of Jinzhou Medical University were included in this study, and all of whom were hospitalized for T2DM from January 2018 to December 2020. The measured acylcarnitines were classified by factor analysis, and the factors were extracted. To determine the correlation between acylcarnitines and DPN, binary logistic regression analysis was applied. Six factors were extracted from 25 acylcarnitines, and the cumulative contribution rate of variance was 61.02%. Plasma levels of short-chain acylcarnitines (C2, C3, C4, and C5) were positively associated with DPN risk
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
